Format

Send to

Choose Destination
Nat Rev Cancer. 2006 Jul;6(7):565-71.

The US Food and Drug Administration perspective on cancer biomarker development.

Author information

1
Office of in vitro Diagnostic Devices, Center for Devices and Radiological Health, Food and Drug Administration, NFZ-440, 2098 Gaither Road, Rockville, Maryland 20857, USA. steve.gutman@fda.hhs.gov

Abstract

Despite the intense interest in biomarker development for cancer management, few biomarker assays for diagnostic uses have been submitted to the US Food and Drug Administration (FDA). What challenges must researchers overcome to bring cancer-detection technologies to the market and, therefore, into clinical use?

PMID:
16794639
DOI:
10.1038/nrc1911
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center